Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2713645 | 0.80 | PLA2G7 (0.44) | PLA2G7ARPOLB | |
| SCHEMBL5148891 | 0.77 | PLA2G7 (0.49) | PLA2G7ARCHRM3 | |
| SCHEMBL7336615 | 0.77 | PLA2G7 (0.49) | PLA2G7CHRM3 | |
| SCHEMBL2714244 | 0.77 | PLA2G7 (0.49) | PLA2G7CHRM3 | |
| SCHEMBL2715902 | 0.77 | PLA2G7 (0.49) | PLA2G7KDM4ELMNAPOLBCHRM3 | |
| SCHEMBL9826417 | 0.75 | PLA2G7 (0.41) | PLA2G7 | |
| SCHEMBL15827421 | 0.74 | PIK3CD (0.35) | KDM4ELMNACYP2C19CHRNA7 | |
| SCHEMBL2185862 | 0.74 | PLA2G7 (0.47) | PLA2G7KDM4ELMNACHRM3 | |
| SCHEMBL13293918 | 0.74 | CHRM3 (0.56) | PLA2G7POLBCHRM3 | |
| SCHEMBL9697351 | 0.72 | POLB (0.32) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179617-A1 | TRICYCLIC COMPOUNDS | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2021-06-17 | — | — | US | disclosed |
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | HTR1B, HTR5A, HTR1A | PLA2G7 435/4885KDM4E 2422/4885LMNA 3961/4885 |
| US-20210179617-A1 | TRICYCLIC COMPOUNDS | BRD4, BET1, BRD3 | PLA2G7 1843/4885KDM4E 767/4885LMNA 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.